Multiple Myeloma News

CAR T cells take on precancers - Nature

CAR T cells take on precancers Nature

J&J multiple myeloma drug gains edge in earlier stage disease - BioPharma Dive

J&J multiple myeloma drug gains edge in earlier stage disease BioPharma Dive

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma - CancerNetwork

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma CancerNetwork

Combination Treatment May Improve Multiple Myeloma Outcomes - Medscape

Combination Treatment May Improve Multiple Myeloma Outcomes Medscape

UK will be first market for Sanofi's subcutaneous Sarclisa - pharmaphorum

UK will be first market for Sanofi's subcutaneous Sarclisa pharmaphorum

Phase 3 MonumenTAL-3 Trial Demonstrates Significant Survival Benefit With Talquetamab-Based Regimens in Relapsed/Refractory Multiple Myeloma - Pharmacy Times

Phase 3 MonumenTAL-3 Trial Demonstrates Significant Survival Benefit With Talquetamab-Based Regimens in Relapsed/Refractory Multiple Myeloma Pharmacy Times

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs” - AJMC

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs” AJMC

Biopharma bites: Germany rethinks rebate reform, Talvey's melanoma win and more from Takeda, Pelago - FirstWord Pharma

Biopharma bites: Germany rethinks rebate reform, Talvey's melanoma win and more from Takeda, Pelago FirstWord Pharma

J&J drops key cancer trial results as Wall Street eyes stock - Yahoo Finance Singapore

J&J drops key cancer trial results as Wall Street eyes stock Yahoo Finance Singapore

Arlo-Cel Shows Promise in Early-Line Relapsed Multiple Myeloma - Targeted Oncology

Arlo-Cel Shows Promise in Early-Line Relapsed Multiple Myeloma Targeted Oncology

Multiple myeloma caregiver: Why I’ll keep donating blood products at UT MD Anderson ‘for Ever’ - UT MD Anderson

Multiple myeloma caregiver: Why I’ll keep donating blood products at UT MD Anderson ‘for Ever’ UT MD Anderson

Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab - The ASCO Post

Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab The ASCO Post

Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma - Oncology News Central

Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma Oncology News Central

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates - Clinical Trials Arena

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates Clinical Trials Arena

Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer - Pfizer

Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer Pfizer

Investigating the Evolution of Cellular Therapy in Multiple Myeloma - CancerNetwork

Investigating the Evolution of Cellular Therapy in Multiple Myeloma CancerNetwork

EHA26: J&J’s multiple myeloma therapies impress with new data - Pharmaceutical Technology

EHA26: J&J’s multiple myeloma therapies impress with new data Pharmaceutical Technology

Striving for a cure for multiple myeloma: What HCPs need to know - Johnson & Johnson

Striving for a cure for multiple myeloma: What HCPs need to know Johnson & Johnson

Combo treatment delays multiple myeloma progression and may improve survival, study finds - Medical Xpress

Combo treatment delays multiple myeloma progression and may improve survival, study finds Medical Xpress

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma - OncLive

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma OncLive

EHA 2026 Multiple Myeloma Highlights Have Worldwide Impact - Targeted Oncology

EHA 2026 Multiple Myeloma Highlights Have Worldwide Impact Targeted Oncology

Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma - Targeted Oncology

Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma Targeted Oncology

From Conference to Practice: Top 5 Takeaways From EHA 2026 - CancerNetwork

From Conference to Practice: Top 5 Takeaways From EHA 2026 CancerNetwork

Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option - Targeted Oncology

Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option Targeted Oncology

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma - Cleveland Clinic

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma Cleveland Clinic

Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma - Targeted Oncology

Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma Targeted Oncology

Talquetamab Plus Daratumumab Combination Reduces Progression Risk by Up to 72% in Phase 3 Relapsed Multiple Myeloma Trial - BioPharm International

Talquetamab Plus Daratumumab Combination Reduces Progression Risk by Up to 72% in Phase 3 Relapsed Multiple Myeloma Trial BioPharm International

[Interview] 'New multiple myeloma drug brought about a miracle when I was about to give up' - koreabiomed.com

[Interview] 'New multiple myeloma drug brought about a miracle when I was about to give up' koreabiomed.com

Nurses in MM Care: Crucial Roles Met with Systemic Barriers - Oncology Nursing News

Nurses in MM Care: Crucial Roles Met with Systemic Barriers Oncology Nursing News

Talquetamab Plus Darzalex Shows 30-Point Progression-Free Survival Gain in Multiple Myeloma - The Clinical Trial Vanguard

Talquetamab Plus Darzalex Shows 30-Point Progression-Free Survival Gain in Multiple Myeloma The Clinical Trial Vanguard

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector - PMLiVE

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector PMLiVE

ASCO26: BMS and J&J debut shining multiple myeloma data - Clinical Trials Arena

ASCO26: BMS and J&J debut shining multiple myeloma data Clinical Trials Arena

Improving how multiple myeloma is understood and treated - Mayo Clinic News Network

Improving how multiple myeloma is understood and treated Mayo Clinic News Network

Teclistamab Improves Outcomes in Relapsed Multiple Myeloma - University of Miami

Teclistamab Improves Outcomes in Relapsed Multiple Myeloma University of Miami

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity - Nature

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity Nature

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma | Newswise - Newswise

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma | Newswise Newswise